

VENTURA COUNTY HEMATOLOGY ONCOLOGY SPECIALISTS

CLINICAL TRIALS OPEN for ENROLLMENT

**OPEN FOR ENROLLMENT**

<i>Status</i>	<b>Study &amp; PI</b>	<b>Phase</b>	<b>Treatment</b>	<b>Patient Population</b>
Opened Dec 2018	<p><b><u>iSpecimen Network</u></b> Collection and Distribution of Remnant and Research Use Only Biospecimens for Novel Research Uses</p> <p><b>Dr. Dalsania/All Sites</b></p>			
Opened April 2021	<p><b><u>AnHeart Therapeutics TRUST-II</u></b> AB-106-G208 A Single-Arm, Open-Label, Multicenter Phase 2 Study to Evaluate the Efficacy and Safety of Taletrectinib in Patients with Advanced or Metastatic ROS1 Positive NSCLC and Other Solid Tumors</p> <p><b>Dr. Dalsania/All Sites</b></p>	II	Taletrectinib	ROS1 positive advanced or metastatic non-small cell lung cancer (NSCLC)
Open	<p>A Phase I, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HMPL-523 in Patients with Relapsed or Refractory Lymphoma</p>	I	HMPL-523	Relapsed or Refractory Lymphoma
<b>Open</b> <b>May 2022</b>	<p><b><u>Alkermes -ARTISTRY-7</u></b> A Phase 3, Multicenter, Open-Label, Randomized Study of Nemvaleukin Alfa in Combination with Pembrolizumab Versus Investigator's Choice Chemotherapy in Patients with Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer</p> <p><b>Dr. Kong/Oxnard</b></p>	III	Nemvaleukin Alfa in Combination with Pembrolizumab Versus Investigator's Choice	Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

VENTURA COUNTY HEMATOLOGY ONCOLOGY SPECIALISTS

CLINICAL TRIALS OPEN for ENROLLMENT

<p><b>Enrollment on HOLD</b></p>	<p><u>PROTOCOL #ESR 22-21698</u></p> <p>Real World Evaluation of the Effectiveness of AZD7442 for Prevention of SARS-CoV-2 Infection in Immuno-Suppressed Cancer Patients</p> <p><b>Dr. Kong/Oxnard</b></p>		<p>AZD7442</p>	<p>Immuno-Suppressed Cancer Patients</p>
<p><b>Just in Time</b></p>	<p><u>SERENA-6:</u> A Phase III, Double-blind, Randomised Study to Assess Switching to AZD9833 (a Next Generation, Oral SERD) + CDK4/6 Inhibitor (Palbociclib or Abemaciclib) vs Continuing Aromatase Inhibitor (Letrozole or Anastrozole) + CDK4/6 Inhibitor in HR+/HER2- MBC Patients with Detectable ESR1 Mutation Without Disease Progression During 1L Treatment with Aromatase Inhibitor + CDK4/6 Inhibitor</p>	<p>III</p>	<p>AZD9833 (a Next Generation, Oral SERD) + CDK4/6 Inhibitor (Palbociclib or Abemaciclib) vs Continuing Aromatase Inhibitor (Letrozole or Anastrozole) + CDK4/6 Inhibitor</p>	
<p><b>Just in Time</b></p>	<p>1) Tempus TIME Trial</p> <p>2) Curis Pharmatech</p>			